Power Laura J, Fasolato Claudia, Barbero Andrea, Wendt David J, Wixmerten Anke, Martin Ivan, Asnaghi M Adelaide
Department of Biomedical Engineering, University of Basel, Gewerbestrasse 14-16, 4123, Allschwil, Switzerland; Department of Biomedicine, University Hospital Basel, University of Basel, Hebelstrasse 20, 4031, Basel, Switzerland.
Department of Physics and Geology, Perugia University, Via Alessandro Pascoli, 06123, Perugia, Italy; Department of Physics, University of Basel, Klingelbergstrasse 82, 4056, Basel, Switzerland.
Biosens Bioelectron. 2020 Oct 15;166:112467. doi: 10.1016/j.bios.2020.112467. Epub 2020 Jul 29.
Nasal chondrocyte-derived engineered cartilage has been demonstrated to be safe and feasible for the treatment of focal cartilage lesions with promising preliminary evidences of efficacy. To ensure the quality of the products and processes, and to meet regulatory requirements, quality controls for identity, purity, and potency need to be developed. We investigated the use of Raman spectroscopy, a nondestructive analytical method that measures the chemical composition of samples, and statistical learning methods for the development of quality controls to quantitatively characterize the starting biopsy and final grafts. We provide a proof-of-concept to show how Raman spectroscopy can be used to identify the types of tissues found in a nasal septal biopsy, i.e., hyaline cartilage and perichondrium, for a novel tissue identity assay. The tissues could be classified with a sensitivity of 89% and specificity of 77%. We also show how clinically relevant and mature nasal chondrocyte-derived engineered cartilage can be assessed with Raman spectroscopy for the development of potency assays. The maturity of engineered grafts, based on the quantified ratio of glycosaminoglycans to DNA and histological score, could be accurately assessed (R = 0.78 and 0.89, respectively, between predicted and measured values). Our results demonstrate the potential of Raman spectroscopy for the development of characterization assays for regenerative therapies that could be integrated into a good manufacturing practice-compliant process.
鼻软骨细胞来源的工程化软骨已被证明用于治疗局灶性软骨损伤是安全可行的,并有初步的有效证据。为确保产品和工艺的质量,并满足监管要求,需要制定身份、纯度和效力的质量控制标准。我们研究了拉曼光谱(一种测量样品化学成分的无损分析方法)和统计学习方法在制定质量控制标准中的应用,以定量表征起始活检组织和最终移植物。我们提供了一个概念验证,展示了拉曼光谱如何用于识别鼻中隔活检中发现的组织类型,即透明软骨和软骨膜,用于一种新型的组织身份测定。这些组织的分类灵敏度为89%,特异性为77%。我们还展示了如何用拉曼光谱评估临床相关且成熟的鼻软骨细胞来源的工程化软骨,以开发效力测定方法。基于糖胺聚糖与DNA的定量比率和组织学评分,可以准确评估工程化移植物的成熟度(预测值与测量值之间的R分别为0.78和0.89)。我们的结果证明了拉曼光谱在开发可整合到符合良好生产规范流程的再生疗法表征测定方法方面的潜力。